妊娠期百日咳免疫接种安全性(PIPS)研究:接种Tdap疫苗孕妇安全性结局的回顾性队列研究
新西兰2013年开展全国回顾性观察研究,评估妊娠期接种Tdap疫苗的安全性。在68,550名符合条件孕妇中,8,178名(11.9%)接种,60,372名(88.1%)未接种。接种未增加早产 labour、子痫前期等主要结局风险,仅哺乳障碍风险显著升高,且对重度子痫前期、早产 labour、早产分娩和产前出血有保护作用。
要点
- 妊娠期接种Tdap未增加早产 labour、子痫前期、子痫、胎儿生长受限或产后出血风险。
- 哺乳障碍是唯一风险显著升高的次要结局。
- Tdap对重度子痫前期、早产 labour、早产分娩和产前出血有保护作用。
核心结论
- 未发现妊娠期接种Tdap疫苗后存在生物学上合理的孕产妇不良结局。
- 本研究进一步表明妊娠期接种Tdap与意外安全风险无关。
研究设计与样本
- 全国回顾性观察研究,使用新西兰关联行政数据集。
- 研究对象为2013年符合在妊娠28至38周接种资助Tdap疫苗的孕妇,共68,550名。
- 主要结局基于WHO和Brighton Collaboration工作组定义的优先不良事件。
- 使用Cox比例风险模型分析Tdap接种对优先孕产妇结局的影响,校正关键混杂变量。
主要发现
- 68,550名符合条件孕妇中,8,178名(11.9%)接种Tdap,60,372名(88.1%)未接种。
- 妊娠期使用Tdap与主要结局(早产 labour、子痫前期、重度子痫前期、子痫、妊娠期高血压、胎儿生长受限、产后出血)发生率增加无关。
- Tdap未增加次要结局(妊娠期糖尿病、产前出血、胎盘早剥、胎膜早破、早产分娩、胎儿窘迫、绒毛膜羊膜炎、产程中或产后孕产妇发热)。
- 哺乳障碍是唯一风险比显著升高的次要孕产妇结局。
- Tdap对重度子痫前期、早产 labour、早产分娩和产前出血有保护作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New Zealand has funded the administration of tetanus, diphtheria and acellular pertussis (Tdap) vaccine during pregnancy to prevent infant pertussis since 2013. The aim of this study was to assess the safety of Tdap vaccine administered to pregnant women as part of a national maternal immunisation programme. METHODS: We conducted a national retrospective observational study using linked administrative New Zealand datasets. The study population consisted of pregnant women eligible to receive funded Tdap vaccination from 28 to 38 weeks gestation in 2013. Primary study outcomes were based on prioritised adverse events for the assessment of vaccine safety in pregnant women, as defined by WHO and Brighton Collaboration taskforces. We examined the effect of Tdap vaccination on prioritised maternal outcomes using Cox proportional hazard models. Adjusted hazard ratios controlled for key confounding variables. RESULTS: In the cohort of 68,550 women eligible to receive funded antenatal Tdap vaccination during 2013, 8178 (11.9%) were vaccinated and 60,372 (88.1%) were unvaccinated. The use of Tdap in pregnancy was not associated with an increase in the rate of primary outcomes, including preterm labour; pre-eclampsia; pre-eclampsia with severe features; eclampsia; gestational hypertension; fetal growth restriction; or post-partum haemorrhage. Tdap also did not increase secondary outcomes, including gestational diabetes mellitus; antenatal bleeding; placental abruption; premature rupture of membranes; preterm delivery; fetal distress; chorioamnionitis; or, maternal fever during or after labour. Lactation disorders was the only secondary maternal outcome with a significantly increased hazard ratio. Tdap vaccine had a protective effect on pre-eclampsia with severe features, preterm labour, preterm delivery, and antenatal bleeding. CONCLUSION: We did not detect any biologically plausible adverse maternal outcomes following Tdap vaccination during pregnancy. This study provides further assurance that Tdap administration during pregnancy is not associated with unexpected safety risks.
引用
- Griffin JB, Yu L, Watson D, et al. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine. 2018. PMID: 30031662. doi:10.1016/j.vaccine.2018.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。